<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02329145</url>
  </required_header>
  <id_info>
    <org_study_id>204069</org_study_id>
    <nct_id>NCT02329145</nct_id>
  </id_info>
  <brief_title>Renal Denervation in Patients With Chronic Heart Failure and Resynchronization Therapy</brief_title>
  <official_title>Renal Denervation in Patients With Chronic Heart Failure and Resynchronization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jagiellonian University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic heart failure is becoming more and more common disease and activation of sympathetic&#xD;
      nervous system plays a crucial role in its development. There is some data allowing to&#xD;
      suspect that one of the new treatment methods- renal denervation, also in patients with&#xD;
      chronic heart failure may lead to decrease of systemic activity sympathetic nervous system&#xD;
      and, as a consequence, to decrease of disease progression. The research hypothesis is whether&#xD;
      renal denervation in case of symptomatic heart failure, even the optimal treatment therapy is&#xD;
      used (including resynchronization therapy), is contributing to the improvement in parameters&#xD;
      of neurohormonal activation, hemodynamics and clinical patient status. The aim of the study&#xD;
      is to obtain a new knowledge concerning renal denervation in chronic heart failure, So far&#xD;
      only very limited data- mostly case reports- are available in this study area.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of hospitalizations due to heart failure worsening.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in NYHA class.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 6 minute walk test distance.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>renal denervation</intervention_name>
    <arm_group_label>Active treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age ≥ 18 year&#xD;
&#xD;
          2. heart failure patients NYHA Class II - IV&#xD;
&#xD;
          3. implanted resynchronization pacemaker according to current european guidelines at&#xD;
             least 6 months earlier&#xD;
&#xD;
          4. symptoms of heart failure even on optimal pharmacological therapy including&#xD;
             resynchronization therapy (lack of improvement within dyspnoea and exercise tolerance&#xD;
             after the procedure)&#xD;
&#xD;
          5. left ventricular ejection function ≤ 35%&#xD;
&#xD;
          6. glomerular filtration rate (eGFR according to MDRD formula ≥ 30 mL/min/1.73m2)&#xD;
&#xD;
          7. patient informed consent for participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. renal artery anatomy not eligible for denervation (at least 4 mm diameter, 20 mm in&#xD;
             length)&#xD;
&#xD;
          2. history of prior renal artery intervention&#xD;
&#xD;
          3. single functioning kidney&#xD;
&#xD;
          4. clinic systolic BP &lt; 110mmHg&#xD;
&#xD;
          5. pregnancy&#xD;
&#xD;
          6. acute coronary syndrome or cerebrovascular event within last 3 months&#xD;
&#xD;
          7. serious medical conditions which may adversely affect safety- clinically significant&#xD;
             peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders&#xD;
             (thrombocytopenia, hemophilia, or significant anemia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aleksander Kusiak, PhD,MD</last_name>
    <phone>+48124247300</phone>
    <email>alek.kusiak@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ist Department of Cardiology, Interventional Electrocardiology and Hypertension</name>
      <address>
        <city>Krakow</city>
        <state>Malopolska</state>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksander Kusiak, MD, PHD</last_name>
      <phone>+48124247300</phone>
      <email>alek.kusiak@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>December 23, 2014</study_first_submitted>
  <study_first_submitted_qc>December 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>December 29, 2014</last_update_submitted>
  <last_update_submitted_qc>December 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jagiellonian University</investigator_affiliation>
    <investigator_full_name>Aleksander Kusiak</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>renal denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

